Investigational Drug Information for SF1126
✉ Email this page to a colleague
What is the development status for investigational drug SF1126?
SF1126 is an investigational drug.
There have been 4 clinical trials for SF1126.
The most recent clinical trial was a Phase 1 trial, which was initiated on November 1st 2016.
The most common disease conditions in clinical trials are Carcinoma, Hepatocellular, Carcinoma, and Neoplasms, Unknown Primary. The leading clinical trial sponsors are SignalRX Pharmaceuticals, Inc., Semafore Pharmaceuticals, and University of Southern California.
There are thirty-one US patents protecting this investigational drug and three hundred and thirty-seven international patents.
Summary for SF1126
| US Patents | 31 |
| International Patents | 337 |
| US Patent Applications | 118 |
| WIPO Patent Applications | 54 |
| Japanese Patent Applications | 17 |
| Clinical Trial Progress | Phase 1 (2016-11-01) |
| Vendors | 22 |
Recent Clinical Trials for SF1126
| Title | Sponsor | Phase |
|---|---|---|
| Phase 1 Study of SF1126 in Combination With Nivolumab in Patients With Advanced Hepatocellular Carcinoma | University of California, San Diego | Phase 1 |
| Phase 1 Study of SF1126 in Combination With Nivolumab in Patients With Advanced Hepatocellular Carcinoma | SignalRX Pharmaceuticals, Inc. | Phase 1 |
| SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes | SignalRX Pharmaceuticals, Inc. | Phase 2 |
Clinical Trial Summary for SF1126
Top disease conditions for SF1126
Top clinical trial sponsors for SF1126
US Patents for SF1126
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| SF1126 | ⤷ Try a Trial | Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity | The University of North Carolina at Chapel Hill (Chapel Hill, NC) | ⤷ Try a Trial |
| SF1126 | ⤷ Try a Trial | Humanized anti-Tn-MUC1 antibodies and their conjugates | ADC Therpeutics S.A. (Epalinges, CH) Medimmune Limited (Cambridge, GB) | ⤷ Try a Trial |
| SF1126 | ⤷ Try a Trial | Benzothiophene-based selective estrogen receptor downregulators | The Board of Trustees of the University of Illinois (Urbana, IL) | ⤷ Try a Trial |
| SF1126 | ⤷ Try a Trial | Combination of PI3K-inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (Berlin, DE) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for SF1126
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| SF1126 | Australia | AU2015244171 | 2034-04-11 | ⤷ Try a Trial |
| SF1126 | Australia | AU2015244179 | 2034-04-11 | ⤷ Try a Trial |
| SF1126 | Canada | CA2945128 | 2034-04-11 | ⤷ Try a Trial |
| SF1126 | Canada | CA2945129 | 2034-04-11 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
